RxDoctor Payments DataLook up a doctor →

Mark Thimineur, MD

Interventional Pain Medicine · Derby, CTNPI 1336180314

Payments from drug & device makers

$16,813in general payments, 2019–2025

Across 540 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Saluda Medical Americas, Inc.$2K
  • Collegium Pharmaceutical, Inc.$1K
  • Boston Scientific$1K
  • AbbVie$1K
  • Biotronik NRO, Inc.$1K
  • plus $5K from 37 others

What the payments were for

  • Consulting fees$4,12825%
  • Food & beverage$12,57575%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$431,340
Medicare patients
428
Services billed
4,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl224$257,257
PercocetOxycodone Hcl/Acetaminophen23$94,263
Xtampza ErOxycodone Myristate79$88,890
Fentanyl112$23,634
BelbucaBuprenorphine Hcl26$21,226
Oxycodone Hcl770$19,800
Nurtec OdtRimegepant Sulfate16$18,712
Aimovig AutoinjectorErenumab-Aooe22$16,505
NucyntaTapentadol Hcl15$16,385
Nucynta ErTapentadol Hcl11$16,166
Morphine Sulfate ErMorphine Sulfate249$11,282
MovantikNaloxegol Oxalate25$11,077
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen219$7,377
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen194$6,835
Sirolimus25$6,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta, Nucynta Er$1,238$142,666131 claims
PfizerNurtec Odt$548$18,71216 claims
Redhill Biopharma Inc.Movantik$15$11,07725 claims
AbbVieLinzess$1,165$5,40711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain medicine providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other interventional pain medicine in Derby

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →